Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2020 Mar 13

PMID 32161598

Citations 33

Authors

Xin Zhang

Dong Wang

Zhidong Li

Defeng Jiao

Linlin Jin

Jingjing Cong

Xiaohu Zheng

Lijun Xu

Affiliations

Soon will be listed here.

Abstract

Gemcitabine has been used as first-line chemotherapy against lung cancer, but many patients experience cancer recurrence. Activation of anti-tumor immunity has become an important way to prevent recurrence. Anti-tumor immune responses are often dependent upon the immunogenicity of tumors. In our study, we observed that low-dose gemcitabine treatment enhanced the immunogenicity of lung cancer by increasing the exposure of calreticulin, high mobility group box 1, and upregulating expression of NKG2D ligands. Further studies demonstrated that low-dose gemcitabine treatment increased interferon-γ expression and NK-cell activation in mice. Low-dose gemcitabine treatment was sufficient for inhibiting tumor growth with few side effects . These data suggest that low-dose gemcitabine-induced immunochemotherapy activated antitumor immunity in immunocompetent patients.

Citing Articles

POU4F1 enhances lung cancer gemcitabine resistance by regulating METTL3-dependent TWF1 mRNA N6 adenosine methylation.

Tang J, Liu Z, Xie G, Wang C, Jiang Y 3 Biotech. 2024; 15(1):7.

PMID: 39676891 PMC: 11638459. DOI: 10.1007/s13205-024-04161-w.

Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization.

Chen S, Zhu H, Jounaidi Y Signal Transduct Target Ther. 2024; 9(1):302.

PMID: 39511139 PMC: 11544004. DOI: 10.1038/s41392-024-02005-w.

Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells.

Khaliulin M, Valiullina A, Petukhov A, Yuan Y, Spada S, Bulatov E Cancer Immunol Immunother. 2024; 74(1):3.

PMID: 39487875 PMC: 11531461. DOI: 10.1007/s00262-024-03817-z.

Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in atypical teratoid/rhabdoid tumors.

Metselaar D, Meel M, Goulding J, du Chatinier A, Rigamonti L, Waranecki P Cell Rep Med. 2024; 5(9):101700.

PMID: 39208799 PMC: 11524974. DOI: 10.1016/j.xcrm.2024.101700.

Investigation of Lung Cancer Cell Response to Cryoablation and Adjunctive Gemcitabine-Based Cryo-Chemotherapy Using the A549 Cell Line.

Santucci K, Snyder K, Van Buskirk R, Baust J, Baust J Biomedicines. 2024; 12(6).

PMID: 38927445 PMC: 11200978. DOI: 10.3390/biomedicines12061239.

References

Ferrari de Andrade L, Tay R, Pan D, Luoma A, Ito Y, Badrinath S . Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. Science. 2018; 359(6383):1537-1542. PMC: 6626532. DOI: 10.1126/science.aao0505. View

Inoue H, Tani K . Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ. 2013; 21(1):39-49. PMC: 3857623. DOI: 10.1038/cdd.2013.84. View

Ghansah T, Vohra N, Kinney K, Weber A, Kodumudi K, Springett G . Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma. Cancer Immunol Immunother. 2013; 62(6):1083-91. PMC: 3666559. DOI: 10.1007/s00262-013-1407-9. View

Van Moorsel C, Pinedo H, Veerman G, Vermorken J, Postmus P, Peters G . Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur J Cancer. 1999; 35(5):808-14. DOI: 10.1016/s0959-8049(99)00004-0. View

Hosomi S, Grootjans J, Tschurtschenthaler M, Krupka N, Matute J, Flak M . Intestinal epithelial cell endoplasmic reticulum stress promotes MULT1 up-regulation and NKG2D-mediated inflammation. J Exp Med. 2017; 214(10):2985-2997. PMC: 5626394. DOI: 10.1084/jem.20162041. View

Liu W, Fowler D, Smith P, Dalgleish A . Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer. 2009; 102(1):115-23. PMC: 2813751. DOI: 10.1038/sj.bjc.6605465. View

Khallouf H, Marten A, Serba S, Teichgraber V, Buchler M, Jager D . 5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I. J Immunother. 2012; 35(3):245-53. DOI: 10.1097/CJI.0b013e31824b3a76. View

Fucikova J, Moserova I, Truxova I, Hermanova I, Vancurova I, Partlova S . High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer. 2014; 135(5):1165-77. DOI: 10.1002/ijc.28766. View

Lanier L . Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008; 9(5):495-502. PMC: 2669298. DOI: 10.1038/ni1581. View

10.

Venereau E, Ceriotti C, Bianchi M . DAMPs from Cell Death to New Life. Front Immunol. 2015; 6:422. PMC: 4539554. DOI: 10.3389/fimmu.2015.00422. View

11.

Cerwenka A, Lanier L . Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol. 2016; 16(2):112-23. DOI: 10.1038/nri.2015.9. View

12.

Obeid M, Tesniere A, Ghiringhelli F, Fimia G, Apetoh L, Perfettini J . Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2006; 13(1):54-61. DOI: 10.1038/nm1523. View

13.

Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I . Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology. 2015; 4(4):e1008866. PMC: 4485780. DOI: 10.1080/2162402X.2015.1008866. View

14.

Matzinger P . Tolerance, danger, and the extended family. Annu Rev Immunol. 1994; 12:991-1045. DOI: 10.1146/annurev.iy.12.040194.005015. View

15.

Diefenbach A, Jensen E, Jamieson A, Raulet D . Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001; 413(6852):165-71. PMC: 3900321. DOI: 10.1038/35093109. View

16.

Garg A, Agostinis P . Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses. Immunol Rev. 2017; 280(1):126-148. DOI: 10.1111/imr.12574. View

17.

Chaudhuri D, Suriano R, Mittelman A, Tiwari R . Targeting the immune system in cancer. Curr Pharm Biotechnol. 2009; 10(2):166-84. DOI: 10.2174/138920109787315114. View

18.

Cella M, Sallusto F, Lanzavecchia A . Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol. 1997; 9(1):10-6. DOI: 10.1016/s0952-7915(97)80153-7. View

19.

Sandler A, Nemunaitis J, DENHAM C, von Pawel J, Cormier Y, Gatzemeier U . Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000; 18(1):122-30. DOI: 10.1200/JCO.2000.18.1.122. View

20.

Suzuki Y, Mimura K, Yoshimoto Y, Watanabe M, Ohkubo Y, Izawa S . Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res. 2012; 72(16):3967-76. DOI: 10.1158/0008-5472.CAN-12-0851. View